Chimeric antigen receptor for adoptive immunotherapy of cancer: Latest research and future prospects

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Shi, Huan ^a   Sun, Meili ^b   Liu, Lin ^a   Wang, Zhehai ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Adoptive transfer; Chimeric antigen receptor; Gene transfer; T cells

Indexed keywords

ALLOPURINOL; CHIMERIC ANTIGEN RECEPTOR; CORTICOSTEROID; CYTOKINE RECEPTOR ANTAGONIST; PEMBROLIZUMAB; RASBURICASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE TRANSFER; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CELL THERAPY; CYTOKINE RELEASE SYNDROME; HUMAN; HUMORAL IMMUNITY; NONHUMAN; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR LYSIS SYNDROME; ADOPTIVE IMMUNOTHERAPY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASMS;

HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84908145811     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-219     Document Type: Review

References (90)

1. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol 2011, 8:577-585. 10.1038/nrclinonc.2011.116, 21808266.
2. Shi H, Liu L, Wang Z. Improving the efficacy and safety of engineered T cell therapy for cancer. Cancer Lett 2013, 328:191-197. 10.1016/j.canlet.2012.09.015, 23022475.
3. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007, 117:1466-1476. 10.1172/JCI32446, 1878537, 17549249.
4. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003, 3:666-675. 10.1038/nrc1167, 2305722, 12951585.
5. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854. 10.1126/science.1076514, 1764179, 12242449.
6. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009, 21:233-240. 10.1016/j.coi.2009.03.002, 3459355, 19304471.
7. Anurathapan U, Leen AM, Brenner MK, Vera JF. Engineered T cells for cancer treatment. Cytotherapy 2014, 16:713-33. 10.1016/j.jcyt.2013.10.002, 24239105.
8. Eshhar Z. The T-body approach: redirecting T cells with antibody specificity. Handb Exp Pharmacol 2008, 181:329-342. 10.1007/978-3-540-73259-4_14, 18071952.
9. Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003, 3:35-45. 10.1038/nrc971, 12509765.
10. Song D-G, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 2012, 119:696-706. 10.1182/blood-2011-03-344275, 22117050.
11. Liu L, Sun M, Wang Z. Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors. Cancer Lett 2012, 316:1-5. 10.1016/j.canlet.2011.10.027, 22099879.
12. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee S-M, Lee T, Pope SH, Riordan GS, Whitlow M. Single-chain antigen-binding proteins. Science 1988, 242:423-426. 10.1126/science.3140379, 3140379.
13. Westwood JA, Smyth MJ, Teng MW, Moeller M, Trapani JA, Scott AM, Smyth FE, Cartwright GA, Power BE, Hönemann D. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci U S A 2005, 102:19051-19056. 10.1073/pnas.0504312102, 1323148, 16365285.
14. Turatti F, Figini M, Alberti P, Willemsen RA, Canevari S, Mezzanzanica D. Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor. J Gene Med 2005, 7:158-170. 10.1002/jgm.647, 15538730.
15. Hudecek M, Lupo-Stanghellini M-T, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, Riddell SR. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 2013, 19:3153-3164. 10.1158/1078-0432.CCR-13-0330, 3804130, 23620405.
16. Shaffer DR, Savoldo B, Yi Z, Chow KK, Kakarla S, Spencer DM, Dotti G, Wu M-F, Liu H, Kenney S. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 2011, 117:4304-4314. 10.1182/blood-2010-04-278218, 3087480, 21304103.
17. Muniappan A, Banapour B, Lebkowski J, Talib S. Ligand-mediated cytolysis of tumor cells: use of heregulin-zeta chimeras to redirect cytotoxic T lymphocytes. Cancer Gene Ther 2000, 7:128. 10.1038/sj.cgt.7700100, 10678365.
18. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 2004, 64:9160-9166. 10.1158/0008-5472.CAN-04-0454, 15604287.
19. Niederman TM, Ghogawala Z, Carter BS, Tompkins HS, Russell MM, Mulligan RC. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci 2002, 99:7009-7014. 10.1073/pnas.092562399, 124519, 11997459.
20. Zhang T, Barber A, Sentman CL. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res 2006, 66:5927-5933. 10.1158/0008-5472.CAN-06-0130, 16740733.
21. Song D-G, Ye Q, Santoro S, Fang C, Best A, Powell DJ. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition. Hum Gene Ther 2013, 24:295-305. 10.1089/hum.2012.143, 3609608, 23297870.
22. Lehner M, Götz G, Proff J, Schaft N, Dörrie J, Full F, Ensser A, Muller YA, Cerwenka A, Abken H. Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One 2012, 7:e31210. 10.1371/journal.pone.0031210, 3280271, 22355347.
23. Zhang T, Wu M-R, Sentman CL. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. J Immunol 2012, 189:2290-2299. 10.4049/jimmunol.1103495, 3633481, 22851709.
24. Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z, Davila E. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res 2012, 18:6436-6445. 10.1158/1078-0432.CCR-12-1449, 23032741.
25. Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, Yu J, Scholler N, Powell DJ. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res 2012, 72:1844-1852. 10.1158/0008-5472.CAN-11-3890, 3319867, 22315351.
26. Kudo K, Imai C, Lorenzini P, Kamiya T, Kono K, Davidoff AM, Chng WJ, Campana D. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res 2014, 74:93-103. 10.1158/0008-5472.CAN-13-1365, 24197131.
27. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368:1509-1518. 10.1056/NEJMoa1215134, 4058440, 23527958.
28. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013, 5:177ra138-177ra138.
29. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011, 121:1822. 10.1172/JCI46110, 3083795, 21540550.
30. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010, 18:843-851. 10.1038/mt.2010.24, 2862534, 20179677.
31. James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, Raubitschek AA, Forman SJ, Press OW. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol 2008, 180:7028-7038. 10.4049/jimmunol.180.10.7028, 2585549, 18453625.
32. Anurathapan U, Chan RC, Hindi HF, Mucharla R, Bajgain P, Hayes BC, Fisher WE, Heslop HE, Rooney CM, Brenner MK. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther 2014, 22:623-33. 10.1038/mt.2013.262, 24213558.
33. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci 1993, 90:720-724. 10.1073/pnas.90.2.720, 45737, 8421711.
34. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006, 12:6106-6115. 10.1158/1078-0432.CCR-06-1183, 2154351, 17062687.
35. Park JR, DiGiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, Meechoovet HB, Bautista C, Chang W-C, Ostberg JR. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007, 15:825-833.
36. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006, 24:e20-e22. 10.1200/JCO.2006.05.9964, 16648493.
37. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008, 112:2261-2271. 10.1182/blood-2007-12-128843, 2532803, 18509084.
38. Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med 1995, 181:1653-1659. 10.1084/jem.181.5.1653, 2192006, 7722445.
39. Bridgeman J S, Hawkins R E, Hombach A A, Abken H, Gilham D E. Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther 2010, 10:77-90. 10.2174/156652310791111001, 20222863.
40. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJ. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006, 66:10995-11004. 10.1158/0008-5472.CAN-06-0160, 17108138.
41. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRζ chain. J Immunol 2004, 172:104-113. 10.4049/jimmunol.172.1.104, 14688315.
42. Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner M. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 2006, 20:1819-1828. 10.1038/sj.leu.2404366, 16932339.
43. Shen C-J, Yang Y-X, Han EQ, Cao N, Wang Y-F, Wang Y, Zhao Y-Y, Zhao L-M, Cui J, Gupta P. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. J Hematol Oncol 2013, 6:33. 10.1186/1756-8722-6-33, 3658918, 23656794.
44. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733. 10.1056/NEJMoa1103849, 3387277, 21830940.
45. Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira ACP, Burbridge SE, Box C, Eccles SA, Maher J. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol 2012, 32:1059-1070. 10.1007/s10875-012-9689-9, 22526592.
46. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013, 31:71-75.
47. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci 2009, 106:3360-3365. 10.1073/pnas.0813101106, 2651342, 19211796.
48. Hombach AA, Abken H. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Int J Cancer 2011, 129:2935-2944. 10.1002/ijc.25960, 22030616.
49. Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012, 119:3940-3950. 10.1182/blood-2011-10-387969, 3350361, 22308288.
50. Moritz D, Groner B. A spacer region between the single chain antibody-and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther 1995, 2:539-546.
51. Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O'Neill A, Irlam J, Chester KA, Kemshead JT, Shaw DM. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother 2005, 28:203-211. 10.1097/01.cji.0000161397.96582.59, 15838376.
52. Hombach A, Hombach A, Abken H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer'domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target'activation and unintended initiation of an innate immune response. Gene Ther 2010, 17:1206-1213. 10.1038/gt.2010.91, 20555360.
53. Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005, 12:933-941. 10.1016/j.ymthe.2005.04.016, 15979412.
54. Schambach A, Swaney WP, van der Loo JC. Design and production of retro-and lentiviral vectors for gene expression in hematopoietic cells. Methods Mol Biol 2009, 506:191-205. 10.1007/978-1-59745-409-4_14, 19110628.
55. Jensen M, Tan G, Forman S, Wu AM, Raubitschek A. CD20 is a molecular target for scFvFc: zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biol Blood Marrow Transplant 1998, 4:75-83. 10.1053/bbmt.1998.v4.pm9763110, 9763110.
56. Patel S, Moskalenko M, Smith D, Maske B, Finer M, McArthur J. Impact of chimeric immune receptor extracellular protein domains on T cell function. Gene Ther 1999, 6:412. 10.1038/sj.gt.3300831, 10435091.
57. Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells. Oncoimmunology 2012, 1:458-466. 10.4161/onci.19855, 3382912, 22754764.
58. Geiger TL, Nguyen P, Leitenberg D, Flavell RA. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood 2001, 98:2364-2371. 10.1182/blood.V98.8.2364, 11588032.
59. Heuser C, Hombach A, Lösch C, Manista K, Abken H. T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells. Gene Ther 2003, 10:1408-1419. 10.1038/sj.gt.3302023, 12900755.
60. Sinn P, Sauter S, McCray P. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther 2005, 12:1089-1098. 10.1038/sj.gt.3302570, 16003340.
61. Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, Hackett PB, Kohn DB, Shpall EJ, Champlin RE. Redirecting specificity of T-cell populations for CD19 using the sleeping beauty system. Cancer Res 2008, 68:2961-2971. 10.1158/0008-5472.CAN-07-5600, 2424272, 18413766.
62. Maiti SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, Rao P, Zhao YJ, Multani A, Yang G. Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother 2013, 36:112-123. 10.1097/CJI.0b013e3182811ce9, 3568214, 23377665.
63. Zhao Y, Zheng Z, Cohen CJ, Gattinoni L, Palmer DC, Restifo NP, Rosenberg SA, Morgan RA. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther 2006, 13:151-159. 10.1016/j.ymthe.2005.07.688, 1473967, 16140584.
64. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010, 70:9053-9061. 10.1158/0008-5472.CAN-10-2880, 2982929, 20926399.
65. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer Immunology Research 2014, 2:112-20. 10.1158/2326-6066.CIR-13-0170, 24579088.
66. Klebanoff CA, Gattinoni L, Restifo NP. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?. J Immunother 2012, 35:651-660. 10.1097/CJI.0b013e31827806e6, 3501135, 23090074.
67. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008, 118:294-305. 10.1172/JCI32103, 2104476, 18060041.
68. Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci 2009, 106:17469-17474. 10.1073/pnas.0907448106, 2762661, 19805141.
69. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C. A human memory T cell subset with stem cell-like properties. Nat Med 2011, 17:1290-1297. 10.1038/nm.2446, 3192229, 21926977.
70. Kaneko S, Mastaglio S, Bondanza A, Ponzoni M, Sanvito F, Aldrighetti L, Radrizzani M, La Seta-Catamancio S, Provasi E, Mondino A. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 2009, 113:1006-1015.
71. Pouw N, Treffers-Westerlaken E, Kraan J, Wittink F, ten Hagen T, Verweij J, Debets R. Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells. Cancer Immunol Immunother 2010, 59:921-931. 10.1007/s00262-010-0818-0, 20101507.
72. Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL, Marincola FM, Wang E, Young HA, Murphy PM, Hwu P. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther 2002, 13:1971-1980. 10.1089/10430340260355374, 12427307.
73. Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, Foster AE. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 2010, 33:780. 10.1097/CJI.0b013e3181ee6675, 2998197, 20842059.
74. Moon EK, Carpenito C, Sun J, Wang L-CS, Kapoor V, Predina J, Powell DJ, Riley JL, June CH, Albelda SM. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 2011, 17:4719-4730. 10.1158/1078-0432.CCR-11-0351, 3612507, 21610146.
75. Song D-G, Ye Q, Carpenito C, Poussin M, Wang L-P, Ji C, Figini M, June CH, Coukos G, Powell DJ. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res 2011, 71:4617-4627. 10.1158/0008-5472.CAN-11-0422, 4140173, 21546571.
76. Parente-Pereira AC, Burnet J, Ellison D, Foster J, Davies DM, van der Stegen S, Burbridge S, Chiapero-Stanke L, Wilkie S, Mather S. Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J Clin Immunol 2011, 31:710-718. 10.1007/s10875-011-9532-8, 21505816.
77. van der Stegen SJ, Davies DM, Wilkie S, Foster J, Sosabowski JK, Burnet J, Whilding LM, Petrovic RM, Ghaem-Maghami S, Mather S. Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity?. J Immunol 2013, 191:4589-4598. 10.4049/jimmunol.1301523, 24062490.
78. van Schalkwyk MC, Papa SE, Jeannon J-P, Urbano TG, Spicer JF, Maher J. Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Human Gene Therapy Clinical Development 2013, 24:134-142. 10.1089/humc.2013.144, 24099518.
79. Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di Re EM, Eggermont AM, Goey SH, Gratama JW, Lamers CH. Regression of advanced ovarian carcinoma by Intraperitoneal treatment with autologous TLymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995, 87:1463-1469. 10.1093/jnci/87.19.1463, 7674333.
80. Duval L, Schmidt H, Kaltoft K, Fode K, Jensen JJ, Sorensen SM, Nishimura MI, von der Maase H. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. Clin Cancer Res 2006, 12:1229-1236. 10.1158/1078-0432.CCR-05-1485, 16489078.
81. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3:95ra73-95ra73. 3393096, 21832238.
82. Choi KA, Lee JE, Kim Y-G, Kim DJ, Kim K, Ko YH, Oh HY, Kim WS, Huh W. Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome. Ann Hematol 2009, 88:639-645. 10.1007/s00277-008-0642-1, 19030857.
83. Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010, 149:578-586. 10.1111/j.1365-2141.2010.08143.x, 20331465.
84. Xu X-J, Tang Y-M. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Cancer Lett 2014, 343:172-178. 10.1016/j.canlet.2013.10.004, 24141191.
85. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. T cells expressing chimeric antigen receptors Can cause anaphylaxis in humans. Cancer Immunology Research 2013, 1:26-31.
86. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12:252-264. 10.1038/nrc3239, 22437870.
87. Brahmer JR, Tykodi SS, Chow LQ, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465. 10.1056/NEJMoa1200694, 3563263, 22658128.
88. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454. 10.1056/NEJMoa1200690, 3544539, 22658127.
89. John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 2013, 19:5636-5646. 10.1158/1078-0432.CCR-13-0458, 23873688.
90. Rossig C. Extending the chimeric receptor-based T-cell targeting strategy to solid tumors. Oncoimmunology 2013, 2:e26091. 10.4161/onci.26091, 3825720, 24244901.